Significance of Angiotensin II Receptor Blocker Lipophilicities and Their Protective Effect against Vascular Remodeling
- 1 January 2005
- journal article
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 28 (7) , 593-600
- https://doi.org/10.1291/hypres.28.593
Abstract
Although the lipophilicities of the various angiotensin II receptor blockers (ARBs) are very different, the relationship between lipophilicity and the protective effect against vascular remodeling is unclear. In this study, we compared the protective effects of a highly lipophilic ARB, telmisartan, and an ARB with low lipophilicity, losartan, on vascular function and oxidative stress in stroke-prone spontaneously hypertensive rats (SHR-SP). SHR-SP received oral placebo, 1 mg/kg telmisartan, or 10 mg/kg losartan for 2 weeks. The blood pressure (BP) in SHR-SP was significantly higher than that in Wistar-Kyoto (WKY) rats before treatment, and the BP was reduced equally in telmisartan- and losartan-treated SHR-SP compared to placebo-treated SHR-SP. Acetylcholine-induced vasorelaxation in isolated carotid arteries was significantly weaker in SHR-SP than in WKY rats, but in both telmisartan- and losartan-treated SHR-SP, acetylcholine-induced vasorelaxation was significantly higher than in placebo-treated SHR-SP. Moreover, acetylcholine-induced vasorelaxation in telmisartan-treated rats was significantly stronger than in losartan-treated SHR-SP. The expression of the endothelial nitric oxide synthase gene was significantly higher in telmisartan- and losartan-treated rats than in placebo-treated SHR-SP, and was significantly higher in telmisartan-treated rats than in losartan-treated rats. In contrast, the expression of the NAD(P)H oxidase subunit p22phox gene in telmisartan-treated SHR-SP was significantly lower than that in losartan-treated SHR-SP. Immunohistochemistry showed that angiotensin II expression in the aorta was significantly lower in telmisartan-treated SHR-SP than in losartan-treated SHR-SP. In conclusion, a highly lipophilic ARB, telmisartan, may be useful for preventing NAD(P)H oxidase activity, and thereby for conferring vascular protection.Keywords
This publication has 33 references indexed in Scilit:
- Effect of Chymase Inhibition on the Arteriovenous Fistula Stenosis in DogsJournal of the American Society of Nephrology, 2005
- Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial Infarction: A Class Effect?Annals of Internal Medicine, 2004
- Significant Target Organs for Hypertension and Cardiac Hypertrophy by Angiotensin-Converting Enzyme InhibitorsHypertension Research, 2004
- Impaired activities of antioxidant enzymes elicit endothelial dysfunction in spontaneous hypertensive rats despite enhanced vascular nitric oxide generationPublished by Oxford University Press (OUP) ,2003
- NAD(P)H Oxidase Inhibition Improves Endothelial Function in Rat and Human Blood VesselsHypertension, 2002
- Captopril and quinapril reduce reactive oxygen speciesEuropean Journal of Clinical Investigation, 2002
- Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone ratsJournal Of Hypertension, 2002
- A Review on Telmisartan: A Novel, Long‐Acting Angiotensin II‐Receptor AntagonistCardiovascular Drug Reviews, 2000
- p22phox mRNA Expression and NADPH Oxidase Activity Are Increased in Aortas From Hypertensive RatsCirculation Research, 1997
- Persistent Tissue Converting Enzyme Inhibition Following Chronic Treatment with Hoe498 and MK421 in Spontaneously Hypertensive RatsJournal of Cardiovascular Pharmacology, 1985